Boobalan Pachaiyappan
Stock Analyst at Roth Capital
(2.04)
# 1,820
Out of 5,050 analysts
20
Total ratings
40%
Success rate
-1.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Boobalan Pachaiyappan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CING Cingulate | Maintains: Buy | $10 → $17 | $3.73 | +355.76% | 3 | Oct 15, 2025 | |
| RNA Avidity Biosciences | Initiates: Buy | $62 | $69.84 | -11.23% | 1 | Sep 17, 2025 | |
| RVPH Reviva Pharmaceuticals Holdings | Reiterates: Buy | $7 → $3 | $0.50 | +495.00% | 2 | Aug 18, 2025 | |
| LGVN Longeveron | Maintains: Buy | $10 → $3 | $0.74 | +307.06% | 2 | Aug 15, 2025 | |
| GANX Gain Therapeutics | Maintains: Buy | $7 → $6 | $1.96 | +206.12% | 3 | Aug 13, 2025 | |
| CRVO CervoMed | Reiterates: Buy | $20 → $16 | $6.92 | +131.21% | 4 | Aug 12, 2025 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $31 → $12 | $5.93 | +102.36% | 2 | Jul 14, 2025 | |
| PYPD PolyPid | Maintains: Buy | $12 → $9 | $3.65 | +146.58% | 2 | Jun 18, 2025 | |
| TRDA Entrada Therapeutics | Initiates: Buy | $29 | $6.91 | +319.68% | 1 | Dec 5, 2024 |
Cingulate
Oct 15, 2025
Maintains: Buy
Price Target: $10 → $17
Current: $3.73
Upside: +355.76%
Avidity Biosciences
Sep 17, 2025
Initiates: Buy
Price Target: $62
Current: $69.84
Upside: -11.23%
Reviva Pharmaceuticals Holdings
Aug 18, 2025
Reiterates: Buy
Price Target: $7 → $3
Current: $0.50
Upside: +495.00%
Longeveron
Aug 15, 2025
Maintains: Buy
Price Target: $10 → $3
Current: $0.74
Upside: +307.06%
Gain Therapeutics
Aug 13, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $1.96
Upside: +206.12%
CervoMed
Aug 12, 2025
Reiterates: Buy
Price Target: $20 → $16
Current: $6.92
Upside: +131.21%
Capricor Therapeutics
Jul 14, 2025
Maintains: Buy
Price Target: $31 → $12
Current: $5.93
Upside: +102.36%
PolyPid
Jun 18, 2025
Maintains: Buy
Price Target: $12 → $9
Current: $3.65
Upside: +146.58%
Entrada Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $29
Current: $6.91
Upside: +319.68%